Report cover image

Global Pneumococcal Polysaccharide Vaccine Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 191 Pages
SKU # APRC20279418

Description

Summary

According to APO Research, the global Pneumococcal Polysaccharide Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Pneumococcal Polysaccharide Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Pneumococcal Polysaccharide Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Pneumococcal Polysaccharide Vaccine market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Pneumococcal Polysaccharide Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Pneumococcal Polysaccharide Vaccine market include Sino Biopharm, Zhifei Biological, Walvax, Merck & Co., Sinovac, Kangtai Bio, Antejin Biotechnology, AIM Bio and Sanofi Pasteur, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Pneumococcal Polysaccharide Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Pneumococcal Polysaccharide Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Pneumococcal Polysaccharide Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Pneumococcal Polysaccharide Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Pneumococcal Polysaccharide Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Pneumococcal Polysaccharide Vaccine sales, projected growth trends, production technology, application and end-user industry.

Pneumococcal Polysaccharide Vaccine Segment by Company

Sino Biopharm
Zhifei Biological
Walvax
Merck & Co.
Sinovac
Kangtai Bio
Antejin Biotechnology
AIM Bio
Sanofi Pasteur
Pfizer
Pneumococcal Polysaccharide Vaccine Segment by Type

PPSV23
PCV13
Others
Pneumococcal Polysaccharide Vaccine Segment by Application

Hospital
Centers for Disease Control and Prevention
Others
Pneumococcal Polysaccharide Vaccine Segment by Region

North America

United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Pneumococcal Polysaccharide Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Pneumococcal Polysaccharide Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Pneumococcal Polysaccharide Vaccine significant trends, drivers, influence factors in global and regions.
6. To analyze Pneumococcal Polysaccharide Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal Polysaccharide Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal Polysaccharide Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal Polysaccharide Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pneumococcal Polysaccharide Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pneumococcal Polysaccharide Vaccine industry.
Chapter 3: Detailed analysis of Pneumococcal Polysaccharide Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Pneumococcal Polysaccharide Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Pneumococcal Polysaccharide Vaccine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

191 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Pneumococcal Polysaccharide Vaccine Sales Value (2020-2031)
1.2.2 Global Pneumococcal Polysaccharide Vaccine Sales Volume (2020-2031)
1.2.3 Global Pneumococcal Polysaccharide Vaccine Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Pneumococcal Polysaccharide Vaccine Market Dynamics
2.1 Pneumococcal Polysaccharide Vaccine Industry Trends
2.2 Pneumococcal Polysaccharide Vaccine Industry Drivers
2.3 Pneumococcal Polysaccharide Vaccine Industry Opportunities and Challenges
2.4 Pneumococcal Polysaccharide Vaccine Industry Restraints
3 Pneumococcal Polysaccharide Vaccine Market by Company
3.1 Global Pneumococcal Polysaccharide Vaccine Company Revenue Ranking in 2024
3.2 Global Pneumococcal Polysaccharide Vaccine Revenue by Company (2020-2025)
3.3 Global Pneumococcal Polysaccharide Vaccine Sales Volume by Company (2020-2025)
3.4 Global Pneumococcal Polysaccharide Vaccine Average Price by Company (2020-2025)
3.5 Global Pneumococcal Polysaccharide Vaccine Company Ranking (2023-2025)
3.6 Global Pneumococcal Polysaccharide Vaccine Company Manufacturing Base and Headquarters
3.7 Global Pneumococcal Polysaccharide Vaccine Company Product Type and Application
3.8 Global Pneumococcal Polysaccharide Vaccine Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Pneumococcal Polysaccharide Vaccine Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Pneumococcal Polysaccharide Vaccine Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Pneumococcal Polysaccharide Vaccine Market by Type
4.1 Pneumococcal Polysaccharide Vaccine Type Introduction
4.1.1 PPSV23
4.1.2 PCV13
4.1.3 Others
4.2 Global Pneumococcal Polysaccharide Vaccine Sales Volume by Type
4.2.1 Global Pneumococcal Polysaccharide Vaccine Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Pneumococcal Polysaccharide Vaccine Sales Volume by Type (2020-2031)
4.2.3 Global Pneumococcal Polysaccharide Vaccine Sales Volume Share by Type (2020-2031)
4.3 Global Pneumococcal Polysaccharide Vaccine Sales Value by Type
4.3.1 Global Pneumococcal Polysaccharide Vaccine Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Pneumococcal Polysaccharide Vaccine Sales Value by Type (2020-2031)
4.3.3 Global Pneumococcal Polysaccharide Vaccine Sales Value Share by Type (2020-2031)
5 Pneumococcal Polysaccharide Vaccine Market by Application
5.1 Pneumococcal Polysaccharide Vaccine Application Introduction
5.1.1 Hospital
5.1.2 Centers for Disease Control and Prevention
5.1.3 Others
5.2 Global Pneumococcal Polysaccharide Vaccine Sales Volume by Application
5.2.1 Global Pneumococcal Polysaccharide Vaccine Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Pneumococcal Polysaccharide Vaccine Sales Volume by Application (2020-2031)
5.2.3 Global Pneumococcal Polysaccharide Vaccine Sales Volume Share by Application (2020-2031)
5.3 Global Pneumococcal Polysaccharide Vaccine Sales Value by Application
5.3.1 Global Pneumococcal Polysaccharide Vaccine Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Pneumococcal Polysaccharide Vaccine Sales Value by Application (2020-2031)
5.3.3 Global Pneumococcal Polysaccharide Vaccine Sales Value Share by Application (2020-2031)
6 Pneumococcal Polysaccharide Vaccine Regional Sales and Value Analysis
6.1 Global Pneumococcal Polysaccharide Vaccine Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Pneumococcal Polysaccharide Vaccine Sales by Region (2020-2031)
6.2.1 Global Pneumococcal Polysaccharide Vaccine Sales by Region: 2020-2025
6.2.2 Global Pneumococcal Polysaccharide Vaccine Sales by Region (2026-2031)
6.3 Global Pneumococcal Polysaccharide Vaccine Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Pneumococcal Polysaccharide Vaccine Sales Value by Region (2020-2031)
6.4.1 Global Pneumococcal Polysaccharide Vaccine Sales Value by Region: 2020-2025
6.4.2 Global Pneumococcal Polysaccharide Vaccine Sales Value by Region (2026-2031)
6.5 Global Pneumococcal Polysaccharide Vaccine Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Pneumococcal Polysaccharide Vaccine Sales Value (2020-2031)
6.6.2 North America Pneumococcal Polysaccharide Vaccine Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Pneumococcal Polysaccharide Vaccine Sales Value (2020-2031)
6.7.2 Europe Pneumococcal Polysaccharide Vaccine Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Pneumococcal Polysaccharide Vaccine Sales Value (2020-2031)
6.8.2 Asia-Pacific Pneumococcal Polysaccharide Vaccine Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Pneumococcal Polysaccharide Vaccine Sales Value (2020-2031)
6.9.2 South America Pneumococcal Polysaccharide Vaccine Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Pneumococcal Polysaccharide Vaccine Sales Value (2020-2031)
6.10.2 Middle East & Africa Pneumococcal Polysaccharide Vaccine Sales Value Share by Country, 2024 VS 2031
7 Pneumococcal Polysaccharide Vaccine Country-level Sales and Value Analysis
7.1 Global Pneumococcal Polysaccharide Vaccine Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Pneumococcal Polysaccharide Vaccine Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Pneumococcal Polysaccharide Vaccine Sales by Country (2020-2031)
7.3.1 Global Pneumococcal Polysaccharide Vaccine Sales by Country (2020-2025)
7.3.2 Global Pneumococcal Polysaccharide Vaccine Sales by Country (2026-2031)
7.4 Global Pneumococcal Polysaccharide Vaccine Sales Value by Country (2020-2031)
7.4.1 Global Pneumococcal Polysaccharide Vaccine Sales Value by Country (2020-2025)
7.4.2 Global Pneumococcal Polysaccharide Vaccine Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.5.2 USA Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.6.2 Canada Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.8.2 Germany Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.9.2 France Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.9.3 France Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.11.2 Italy Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.12.2 Spain Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.13.2 Russia Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.16.2 China Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.16.3 China Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.17.2 Japan Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.19.2 India Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.19.3 India Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.20.2 Australia Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.24.2 Chile Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.26.2 Peru Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.28.2 Israel Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.29.2 UAE Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.31.2 Iran Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Pneumococcal Polysaccharide Vaccine Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Pneumococcal Polysaccharide Vaccine Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Pneumococcal Polysaccharide Vaccine Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Sino Biopharm
8.1.1 Sino Biopharm Comapny Information
8.1.2 Sino Biopharm Business Overview
8.1.3 Sino Biopharm Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2020-2025)
8.1.4 Sino Biopharm Pneumococcal Polysaccharide Vaccine Product Portfolio
8.1.5 Sino Biopharm Recent Developments
8.2 Zhifei Biological
8.2.1 Zhifei Biological Comapny Information
8.2.2 Zhifei Biological Business Overview
8.2.3 Zhifei Biological Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2020-2025)
8.2.4 Zhifei Biological Pneumococcal Polysaccharide Vaccine Product Portfolio
8.2.5 Zhifei Biological Recent Developments
8.3 Walvax
8.3.1 Walvax Comapny Information
8.3.2 Walvax Business Overview
8.3.3 Walvax Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2020-2025)
8.3.4 Walvax Pneumococcal Polysaccharide Vaccine Product Portfolio
8.3.5 Walvax Recent Developments
8.4 Merck & Co.
8.4.1 Merck & Co. Comapny Information
8.4.2 Merck & Co. Business Overview
8.4.3 Merck & Co. Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2020-2025)
8.4.4 Merck & Co. Pneumococcal Polysaccharide Vaccine Product Portfolio
8.4.5 Merck & Co. Recent Developments
8.5 Sinovac
8.5.1 Sinovac Comapny Information
8.5.2 Sinovac Business Overview
8.5.3 Sinovac Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2020-2025)
8.5.4 Sinovac Pneumococcal Polysaccharide Vaccine Product Portfolio
8.5.5 Sinovac Recent Developments
8.6 Kangtai Bio
8.6.1 Kangtai Bio Comapny Information
8.6.2 Kangtai Bio Business Overview
8.6.3 Kangtai Bio Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2020-2025)
8.6.4 Kangtai Bio Pneumococcal Polysaccharide Vaccine Product Portfolio
8.6.5 Kangtai Bio Recent Developments
8.7 Antejin Biotechnology
8.7.1 Antejin Biotechnology Comapny Information
8.7.2 Antejin Biotechnology Business Overview
8.7.3 Antejin Biotechnology Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2020-2025)
8.7.4 Antejin Biotechnology Pneumococcal Polysaccharide Vaccine Product Portfolio
8.7.5 Antejin Biotechnology Recent Developments
8.8 AIM Bio
8.8.1 AIM Bio Comapny Information
8.8.2 AIM Bio Business Overview
8.8.3 AIM Bio Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2020-2025)
8.8.4 AIM Bio Pneumococcal Polysaccharide Vaccine Product Portfolio
8.8.5 AIM Bio Recent Developments
8.9 Sanofi Pasteur
8.9.1 Sanofi Pasteur Comapny Information
8.9.2 Sanofi Pasteur Business Overview
8.9.3 Sanofi Pasteur Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2020-2025)
8.9.4 Sanofi Pasteur Pneumococcal Polysaccharide Vaccine Product Portfolio
8.9.5 Sanofi Pasteur Recent Developments
8.10 Pfizer
8.10.1 Pfizer Comapny Information
8.10.2 Pfizer Business Overview
8.10.3 Pfizer Pneumococcal Polysaccharide Vaccine Sales, Value and Gross Margin (2020-2025)
8.10.4 Pfizer Pneumococcal Polysaccharide Vaccine Product Portfolio
8.10.5 Pfizer Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Pneumococcal Polysaccharide Vaccine Value Chain Analysis
9.1.1 Pneumococcal Polysaccharide Vaccine Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Pneumococcal Polysaccharide Vaccine Sales Mode & Process
9.2 Pneumococcal Polysaccharide Vaccine Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Pneumococcal Polysaccharide Vaccine Distributors
9.2.3 Pneumococcal Polysaccharide Vaccine Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.